Save the date for our SPARK-BIH Call in June 2023!
A SPARK-BIH funded project on the development of an innovative tumor-specific immunotherapy for the treatment of B-cell lymphomas has successfully been awarded a follow-on BMBF grant for a first-in-human clinical trial.
Two SPARK-BIH funded teams network with investors and the life science industry at the international JPM BIO Partnering Event.
Dr. Angelika Vlachou, Principal at High-Tech Gründerfonds (HTGF), supported 25 translational SPARK project teams with a dedicated hands-on Pitch Training Workshop.
SPARK-BIH and NeuroCure organized a second Design Thinking workshop.
After the successful implementation of the NeuroCure/SPARK program, NeuroCure and SPARK-BIH prolong their collaboration and will run a second call for projects.
Researchers led by our SPARKee Ulrike Stein of the ECRC and Robert Preißner of Charité report in "Clinical and Translational Medicine" that statins inhibit a gene that promotes cancer cell metastasis.
NeuroCure grants funding extension to the four NeuroCure/SPARK-BIH teams for an additional year.
We are a mentoring network aiming to accelerate the translation of academic inventions into clinically relevant therapies, diagnostics and medical devices.
Validate your research findings and translate them into therapies, products or services to help patients.
Share your expertise with our SPARKees and participate in our program as SPARK advisor.
SPARK-BIH is a member of the SPARK Global network